Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT03784599
- Locations
- 🇳🇱
Univercity Medical Center Groningen, Groningen, Netherlands
🇳🇱Maastricht UMC+, Maastricht, Limburg, Netherlands
🇳🇱Antoni van Leeuwenhoek ziekenhuis - Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 366
- Registration Number
- NCT03778229
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 40
- Registration Number
- NCT03769103
- Locations
- 🇨🇦
BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
- Conditions
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT03755102
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT03732352
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT03667820
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Osimertinib In EGFR Mutant Lung Cancer
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03586453
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03567642
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 330
- Registration Number
- NCT03543683
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03535363
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Maimi Cancer Institute - Baptist Health South Florida, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.